GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis (GDF 15)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01201135|
Recruitment Status : Unknown
Verified September 2010 by Wolfson Medical Center.
Recruitment status was: Not yet recruiting
First Posted : September 14, 2010
Last Update Posted : September 14, 2010
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Patients With Thalassemia Intermedia, Congenital Dyserythropoietic Anemia Type I|
The identification of the ferroportin/hepcidin axis has allowed the effect of erythroid activity on iron balance to be studied and has created the basis for better defining the erythroid regulators.
In iron-loading anemias, ineffective erythropoiesis suppresses hepcidin production, which result in dysregulating iron homeostasis. Miller and co-workers showed that release of cytokines like growth differentiation factor 15 (GDF15) during the process of ineffective erythropoiesis inhibits hepcidin production, thus defining a molecular link between ineffective erythropoiesis, suppression of hepcidin production and parenchymal iron loading.
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||The Impact of Growth Differentiating Factor (GDF) 15 in Sickle Cell Disease and Hereditary Spherocytosis|
|Study Start Date :||September 2010|
|Estimated Primary Completion Date :||September 2011|
|Estimated Study Completion Date :||September 2011|
|Sickle cell disease|
- GDF 15 [ Time Frame: year ]
- Hepcidine [ Time Frame: year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||5 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
The study will contain 40 patients with Sickle cell disease and 40 patients with hereditary spherocytosis.
After ICF (Informed Consent Form) has been signed by the patients the following laboratory tests will be taken once during the study:
- GDF 15( 3ml of serum) (at the laboratory of hematology at Wolfson Medical Center/Israel)
- Hepcidine (3ml of serum) (at the laboratory of Prof. T. Ganz, USA). The blood samples should be taken at least one week apart from blood transfusion.
In case of infection or acute inflammation , blood samples should be taken only one week after resolution of these conditions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01201135
|Contact: Ghoti Hossam, email@example.com|
|Principal Investigator:||GHOTI HOSSAM, doctor||HEMATOLOGY DEPARTMENT ON WOLFSSON MEDICAL CENTER|
|Responsible Party:||Dr' Ghoti Hossam, hematology department on Wolfsson Medical Center|
|Other Study ID Numbers:||
|First Posted:||September 14, 2010 Key Record Dates|
|Last Update Posted:||September 14, 2010|
|Last Verified:||September 2010|
Anemia, Sickle Cell
Anemia, Dyserythropoietic, Congenital
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn